Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis

Joseph K Han, Claus Bachert, Stella E Lee, Claire Hopkins, Enrico Heffler, Peter W Hellings, Anju T Peters, Siddhesh Kamat, Diane Whalley, Shanshan Qin, Lauren Nelson, Shahid Siddiqui, Asif H Khan, Yongtao Li, Leda P Mannent, Isabelle Guillemin, Chien-Chia Chuang, Joseph K Han, Claus Bachert, Stella E Lee, Claire Hopkins, Enrico Heffler, Peter W Hellings, Anju T Peters, Siddhesh Kamat, Diane Whalley, Shanshan Qin, Lauren Nelson, Shahid Siddiqui, Asif H Khan, Yongtao Li, Leda P Mannent, Isabelle Guillemin, Chien-Chia Chuang

Abstract

Objectives/hypothesis: Clinical trials of biologics to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) have evaluated objective outcomes (e.g., University of Pennsylvania Smell Identification Test [UPSIT], nasal polyps score [NPS], and computed tomography Lund-Mackay score [CT-LMK]) and patient-reported symptoms (e.g., nasal congestion/obstruction [NC], loss of smell [LoS], and total symptom score [TSS]). We estimated anchor-based thresholds for clinically meaningful change in objective and patient-reported outcomes in patients with CRSwNP using data from LIBERTY NP SINUS-24 and SINUS-52 trials (NCT02912468; NCT02898454).

Methods: Target patient-reported outcomes were NC, LoS, and TSS; target objective outcomes were UPSIT, NPS, and CT-LMK. Anchor measures were the 22-item sinonasal outcome test (SNOT-22) rhinologic symptoms domain and total score and rhinosinusitis visual analog scale (VAS). The appropriateness of each anchor measure was evaluated by reviewing correlations between change in anchor measures and target outcomes and descriptive scores on target outcomes by levels of change in the anchor measure. Established thresholds for anchor measures (3.8 points for SNOT-22 rhinologic symptoms, 8.9 points for SNOT-22 total, 1-category improvement for rhinosinusitis VAS) were used to estimate clinically meaningful score changes for each target outcome.

Results: Based on correlations between change in anchor measures and target outcomes, SNOT-22 rhinologic symptoms domain was deemed the most appropriate anchor measure. Using this anchor measure, thresholds for clinically meaningful within-patient change were NC: 1 point; LoS: 1 point; TSS: 3 points; UPSIT: 8 points; NPS: 1 point; and CT-LMK: 5 points.

Conclusion: These thresholds support interpretation of efficacy results for target outcomes in CRSwNP trials.

Level of evidence: 2 Laryngoscope, 132:265-271, 2022.

Keywords: Adult rhinology; nose and paranasal sinuses; quality of life.

© 2021 Sanofi Genzyme and RTI Health Solutions. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.

References

    1. Alobid I, Antón E, Armengot M, et al. SEAIC‐SEORL. Consensus document on nasal polyposis. POLINA Project. J Investig Allergol Clin Immunol 2011;21:1–58.
    1. Huvenne W, van Bruaene N, Zhang N, et al. Chronic rhinosinusitis with and without nasal polyps: what is the difference? Curr Allergy Asthma Rep 2009;9:213–220.
    1. Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross‐sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2019;57:32–42.
    1. Banerji A, Piccirillo JF, Thawley SE, et al. Chronic rhinosinusitis patients with polyps or polypoid mucosa have a greater burden of illness. Am J Rhinol 2007;21:19–26.
    1. Rudmik L, Smith TL. Quality of life in patients with chronic rhinosinusitis. Curr Allergy Asthma Rep 2011;11:247–252.
    1. Dietz de Loos DA, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope 2013;123:57–63.
    1. Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: a link for asthma severity. Curr Allergy Asthma Rep 2010;10:194–201.
    1. Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol 2016;6:373–377.
    1. Håkansson K, Bachert C, Konge L, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported. PLoS One 2015;10:e0127228.
    1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet 2019;394:1638–1650.
    1. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 2017;140:1024–1031.e14.
    1. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146:595–605.
    1. Gevaert P, Lang‐Loidolt D, Lackner A, et al. Nasal IL‐5 levels determine the response to anti‐IL‐5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133–1141.
    1. Zangrilli JG, Maspero J, Harrison T, Werkstrom V, Wu Y. Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials. Pneumologie 2019;73:P254.
    1. Weinstein SF, Katial RK, Bardin P, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self‐reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2019;7:589–596.e3.
    1. Nelsen L, Bradford ES, Bratton DJ, Albers FC, Brusselle G. Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma. Eur Respir J 2017;50:PA3583.
    1. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110–116.e1.
    1. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti‐IL‐5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011;128:989–995.e1–8.
    1. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. Jama 2016;315:469–479.
    1. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double‐blind, placebo‐controlled trial of anti‐IgE for chronic rhinosinusitis. Rhinology 2010;48:318–324.
    1. Hellings PW, Verhoeven E, Fokkens WJ. State‐of‐the‐art overview on biological treatment for CRSwNP. Rhinology 2021;59:151–163.
    1. Food and Drug Administration (FDA) . Guidance for industry patient‐reported outcome measures: Use in medical product development to support labeling claims 2009. Available at: . Accessed October 24, 2018.
    1. Food and Drug Administration (FDA) Patient‐focused drug development guidance public workshop: methods to identify what is important to patients and select, develop or modify fit‐for‐purpose clinical outcomes assessments 2018. Available at: . Accessed March 11, 2021.
    1. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient‐reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:163–169.
    1. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22‐item sinonasal outcome test. Clin Otolaryngol 2009;34:447–454.
    1. DeConde AS, Mace JC, Bodner T, et al. SNOT‐22 quality of life domains differentially predict treatment modality selection in chronic rhinosinusitis. Int Forum Allergy Rhinol 2014;4:972–979.
    1. DeConde AS, Bodner TE, Mace JC, Smith TL. Response shift in quality of life after endoscopic sinus surgery for chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg 2014;140:712–719.
    1. Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT‐22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol 2017;7:1149–1155.
    1. Lidder AK, Detwiller KY, Price CP, et al. Evaluating metrics of responsiveness using patient‐reported outcome measures in chronic rhinosinusitis. Int Forum Allergy Rhinol 2017;7:128–134.
    1. Lim M, Lew‐Gor S, Darby Y, Brookes N, Scadding G, Lund VJ. The relationship between subjective assessment instruments in chronic rhinosinusitis. Rhinology 2007;45:144–147.
    1. Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 2012;50:1–298.
    1. Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health‐related quality of life measures. COPD 2005;2:63–67.
    1. Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 2010;8:89.
    1. European Medicines Agency Committee for Medicinal Products for Human Use . Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. Doc. Ref. EMA/CHMP/EWP/139391/2004 2005. London, UK: European Medicines Agency. Available at: . Accessed March 11, 2021.
    1. Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1–7.
    1. Browne JP, van der Meulen JH, Lewsey JD, Lamping DL, Black N. Mathematical coupling may account for the association between baseline severity and minimally important difference values. J Clin Epidemiol 2010;63:865–874.
    1. Phillips KM, Hoehle LP, Caradonna DS, Gray ST, Sedaghat AR. Minimal clinically important difference for the 22‐item sinonasal outcome test in medically managed patients with chronic rhinosinusitis. Clin Otolaryngol 2018;43:1328–1334.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit